Xinyao Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinyao Qiu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Hongyang Wang
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
11 shared publications - Siyun Shen
The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
10 shared publications - Yanjing Zhu
Southeast University,State Key Laboratory of Millimeter Waves, and the Frontiers Science Center for Mobile Information Communication and Security,Nanjing,China,210096
10 shared publications - Bo Zheng
Department of Emergency Medicine, University of Ottawa, Ottawa, Canada
9 shared publications Jianmin Wu
9 shared publications- Kaiting Wang
Department of Medicine, Henan Medical College
9 shared publications
Latest Publications
- Open Access
- 8 December 2023
- Published by Springer Nature in Phenomics
- Vol. 3 (6) , 549-564
A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma
It is widely recognized that tumor immune microenvironment (TIME) plays a crucial role in tumor progression, metastasis, and therapeutic response. Despite several noninvasive strategies have emerged for cancer diagnosis and prognosis, there are still lack of effective radiomic-based model to evaluate TIME status, let alone predict clinical outcome and immune checkpoint inhibitor (ICIs) response for hepatocellular carcinoma (HCC). In this study, we developed a radiomic model to evaluate TIME status within the tumor and predict prognosis and immunotherapy response. A total of 301 patients who underwent magnetic resonance imaging (MRI) examinations were enrolled in our study. The intra-tumoral expression of 17 immune-related molecules were evaluated using co-detection by indexing (CODEX) technology, and we construct Immunoscore (IS) with the least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression method to evaluate TIME. Of 6115 features extracted from MRI, five core features were filtered out, and the Radiomic Immunoscore (RIS) showed high accuracy in predicting TIME status in testing cohort (area under the curve = 0.753). More importantly, RIS model showed the capability of predicting therapeutic response to anti-programmed cell death 1 (PD-1) immunotherapy in an independent cohort with advanced HCC patients (area under the curve = 0.731). In comparison with previously radiomic-based models, our integrated RIS model exhibits not only higher accuracy in predicting prognosis but also the potential guiding significance to HCC immunotherapy.
- 8 December 2023
- Published by Springer Nature in Phenomics
- Vol. 3 (6) , 549-564
Open AccessA Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma
It is widely recognized that tumor immune microenvironment (TIME) plays a crucial role in tumor progression, metastasis, and therapeutic response. Despite several noninvasive strategies have emerged for cancer diagnosis and prognosis, there are still lack of effective radiomic-based model to evaluate TIME status, let alone predict clinical outcome and immune checkpoint inhibitor (ICIs) response for hepatocellular carcinoma (HCC). In this study, we developed a radiomic model to evaluate TIME status within the tumor and predict prognosis and immunotherapy response. A total of 301 patients who underwent magnetic resonance imaging (MRI) examinations were enrolled in our study. The intra-tumoral expression of 17 immune-related molecules were evaluated using co-detection by indexing (CODEX) technology, and we construct Immunoscore (IS) with the least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression method to evaluate TIME. Of 6115 features extracted from MRI, five core features were filtered out, and the Radiomic Immunoscore (RIS) showed high accuracy in predicting TIME status in testing cohort (area under the curve = 0.753). More importantly, RIS model showed the capability of predicting therapeutic response to anti-programmed cell death 1 (PD-1) immunotherapy in an independent cohort with advanced HCC patients (area under the curve = 0.731). In comparison with previously radiomic-based models, our integrated RIS model exhibits not only higher accuracy in predicting prognosis but also the potential guiding significance to HCC immunotherapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies.Significance:This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies.Significance:This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods